| [1] |
Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review[J]. 2006, 367(9516):1066-1074.
|
| [2] |
Madeiro AP, Rufino AC, Lacerda EZ, et al. Incidence and determinants of severe maternal morbidity: a transversal study in a referral hospital in Teresina, Piaui, Brazil[J]. BMC Pregnancy Childbirth, 2015, 15:210.
|
| [3] |
Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period[J]. Obstet Gynecol, 2015, 125(2):521-525.
|
| [4] |
Olson-Chen C, Seligman NS. Hypertensive Emergencies in Pregnancy[J]. Crit Care Clin, 2016, 32(1):29-41.
|
| [5] |
Too GT, Hill JB. Hypertensive crisis during pregnancy and postpartum period[J]. Semin Perinatol, 2013, 37(4):280-287.
|
| [6] |
Clark SM, Dunn HE, Hankins GD. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy[J]. Semin Perinatol, 2015, 39(7):548-555.
|
| [7] |
Magee LA, Namouz-Haddad S, Cao V, et al. Labetalol for hypertension in pregnancy[J]. Expert Opin Drug Saf, 2015, 14(3):453-461.
|
| [8] |
中华医学会妇产科学分会妊娠期高血压疾病组学. 妊娠期高血压疾病诊治指南(2015)[J]. 中华妇产科杂志，2015, 50(10):721-728.
|
| [9] |
Firoz T, Magee LA, Macdonell K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review[J]. BJOG, 2014, 121(10):1210-1218.
|
| [10] |
Xie RH, Guo Y, Krewski D, et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 175:124-128.
|
| [11] |
Meidahl PK, Jimenez-Solem E, Andersen JT, et al. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study[J]. BMJ Open, 2012, 2(4). pii: e001185.
|
| [12] |
Tsatsaris V, Cabrol D, Carbonne B. Pharmacokinetics of tocolytic agents[J]. Clin Pharmacokinet, 2004, 43(13):833-844.
|
| [13] |
Arulkumaran N, Lightstone L. Severe pre-eclampsia and hypertensive crises[J]. Best Pract Res Clin Obstet Gynaecol, 2013, 27(6):877-884.
|
| [14] |
Alexander JM, Wilson KL. Hypertensive emergencies of pregnancy[J]. Obstet Gynecol Clin North Am, 2013, 40(1):89-101.
|
| [15] |
Shi Q, Leng W, Yao Q, et al. Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy[J]. Int J Cardiol, 2015, 178:162-164.
|
| [16] |
Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade[J]. Br J Obstet Gynaecol, 1994, 101(3):262-263.
|
| [17] |
Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia[J]. Am J Obstet Gynecol, 2005, 193(1):153-163.
|
| [18] |
Al KK, Sequeira RP, Alkhaja AK, et al. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations[J]. J Hypertens, 2014, 32(3):454-463.
|
| [19] |
Delgado De Pasquale S, Velarde R, Reyes O, et al. Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial[J]. Pregnancy Hypertens, 2014, 4(1):19-22.
|
| [20] |
Nij BS, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature[J]. Obstet Gynecol Surv, 2010, 65(5):341-347.
|
| [21] |
Hanff LM, Vulto AG, Bartels PA, et al. Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients[J]. J Hypertens, 2005, 23(12):2319-2326.
|
| [22] |
Nooij LS, Visser S, Meuleman T, et al. The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine[J]. Curr Pharm Biotechnol, 2014, 15(1):64-69.
|
| [23] |
Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines[J]. PLoS One, 2014, 9(12):e113715.
|
| [24] |
Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014[J]. Aust N Z J Obstet Gynaecol, 2015, 55(5):e1-e29.
|
| [25] |
Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus[J]. Cochrane Database Syst Rev, 2009, (1):CD004661.
|
| [26] |
Ganzevoort W, Rep A, Bonsel GJ, et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia[J]. BJOG, 2005, 112(10):1358-1368.
|
| [27] |
Brownfoot FC, Gagliardi DI, Bain E, et al. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth[J]. Cochrane Database Syst Rev, 2013, 8:CD006764.
|
| [28] |
Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments[J]. Am J Obstet Gynecol, 2004, 190(4):878-881.
|
| [29] |
Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review[J]. BMC Pregnancy Childbirth, 2009, 9:8.
|
| [30] |
Kattah AG, Garovic VD. The management of hypertension in pregnancy[J]. Adv Chronic Kidney Dis, 2013, 20(3):229-239.
|
| [31] |
Dennis AT, Chambers E, Serang K. Blood pressure assessment and first-line pharmacological agents in women with eclampsia[J]. Int J Obstet Anesth, 2015, 24(3):247-251.
|
| [32] |
Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women[J]. Curr Hypertens Rep, 2011, 13(5):338-346.
|
| [33] |
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002[J]. Obstet Gynecol, 2002, 99(1):159-167.
|
| [34] |
Duhig KE, Shennan AH. Recent advances in the diagnosis and management of pre-eclampsia[J]. F1000Prime Rep, 2015, 7:24.
|
| [35] |
Duhig KE, Shennan AH. CORRIGENDUM TO: Recent advances in the diagnosis and management of pre-eclampsia[J]. F1000Prime Rep, 2015, 7.pii: 24.
|
| [36] |
Ertan AK, Wagner S, Hendrik HJ, et al. Clinical and biophysical aspects of HELLP-syndrome[J]. J Perinat Med, 2002, 30(6):483-489.
|
| [37] |
Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count[J]. Obstet Gynecol, 2004, 103(5 Pt 1):981-991.
|
| [38] |
Martin JJ. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia)[J]. Int J Gynaecol Obstet, 2013, 121(3):202-207.
|
| [39] |
Woudstra DM, Chandra S, Hofmeyr GJ, et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy[J]. Cochrane Database Syst Rev, 2010, (9):CD008148.
|
| [40] |
Martin JJ, Thigpen BD, Rose CH, et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome[J]. Am J Obstet Gynecol, 2003, 189(3):830-834.
|
| [41] |
Gul A, Cebeci A, Aslan H, et al. Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome[J]. Gynecol Obstet Invest, 2005, 59(2):113-118.
|
| [42] |
Dusse LM, Alpoim PN, Silva JT, et al. Revisiting HELLP syndrome[J]. Clin Chim Acta, 2015, 451(Pt B):117-120.
|